Citations

Clear

634 citation(s) found for "Hall, A".

United States Public Health Laboratory Experiences with Krabbe Disease Newborn Screening After Recommendation at the National Level
Culshaw-Klein, Zoë , Mestel, Kaegan, Kirschner, Alison La Pean , Brackbill, Lesa , Baker, Mei Wang , Hall, Patricia , White, Amy

Mayo Clinic

International Journal of Neonatal Screening | October 30, 2026 | Volume: 12 | Issue: 4 | Pages: 94

10.3390/ijns12040094 Get It

Krabbe disease (KD) is a rare, inherited leukodystrophy associated with early mortality. Infantile Krabbe disease (IKD) was added to the Recommended Uniform Screening Panel (RUSP) in July 2024. Since then, U.S. states have continued to evaluate implementing KD newborn screening (NBS), and RUSP inclusion has hastened adoption efforts. This study aimed to characterize NBS program responses to this recommendation and identify factors influencing adoption and implementation. A mixed-methods approach was used, including a case review of Wisconsin’s process to add conditions to its NBS panel and a cross-sectional survey of U.S. NBS programs. Responses were obtained from 50 of 51 NBS programs. Twenty-two programs actively screen for KD, with ten additional programs in the implementation process. Screening approaches varied, particularly in psychosine (PSY) cutoff thresholds and testing algorithms. Programs reported a range of adoption pathways, including legislative mandates, advisory committee review, and state-specific nomination processes. Key factors impacting KD NBS adoption included uncertainty regarding treatment safety, efficacy, and availability, ethical considerations related to identifying later-onset disease, and logistical challenges such as laboratory readiness and clinical follow-up resources. This study provides a contemporary overview of national implementation of KD NBS and offers practical insights for programs considering adoption.
Designing Faculty Development for AI Skill Building in Health Professions Education: Applied Insights from a Longitudinal Program
Pylman, Stacey , Hall, Elissa , Billings, Heather , Suh, Boyung , Anderson, Tonya V. , Parikh, Priti, Rush, Emily , Hurtubise, Larry , Lowry, John

Mayo Clinic

MedEdPublish | October 5, 2026 | Volume: 16 | Issue: No issue available | Pages: 126

10.12688/mep.21847.1 Get It

AI skill development is essential in health professions education (HPE), yet this type of faculty development is complex to design and implement. While competency frameworks and AI education programs are emerging, many faculty developers are themselves still building AI literacy and confidence, and practical guidance for how to design a faculty development program on AI that is accessible, skill-oriented, and responsive to rapid technological change remains limited. Although webinars and workshops can only do so much, a well-planned faculty development program can provide a great introduction to AI, alleviate fears, and inspire participants to keep growing and learning. Drawing on our experience designing and hosting the AAMC GEA AI Skill-Building Webinar Series and the current literature in AI, this article offers twelve practical tips for faculty developers who are creating AI-focused learning opportunities for everyone involved in HPE. These tips will help readers create robust AI skill-building sessions that move participants beyond awareness of AI and shift their perspectives toward applied, reflective, and responsible use of AI in HPE.
Application of CLIR-Based Post-Analytical Tools to Dutch NBS Data Demonstrates Its Potential Impact on the Performance of CPT1, GA-1, IVA and MSUD Screening in a Disorder-Specific Way
Meijer, Nils W. F., Maase, Rose, Hall, Patricia L., Visser, Wouter F. , Koop, Klaas , Heiner‐Fokkema, M. Rebecca , Velden, Monique G.M. de Sain–van der , Bosch, Annet M , Heiner-Fokkema, M Rebecca , de Sain-van der Velden, Monique G M

Mayo Clinic

International Journal of Neonatal Screening | August 24, 2026 | Volume: 12 | Issue: 3 | Pages: 70

10.3390/ijns12030070 | PMID 42782614 Get It

Newborn screening (NBS) for inborn errors of metabolism is challenged by high false-positive rates, which may lead to parental anxiety and increased healthcare costs associated with diagnostic follow-up. False-positive results often arise from changes in metabolite concentrations that mimic metabolic disorders as a consequence of differences in perinatal factors or nutritional status. To address this, Collaborative Laboratory Integrative Reports (CLIR) and the associated post-analytical tools (PATs) using multivariate interpretation and covariate-adjusted reference intervals may be used to improve specificity of NBS algorithms. In the current study, we examined whether CLIR can be applied to optimize the Dutch NBS program by reducing the false-positive rates. We developed and validated a CLIR-based PAT for CPT1 deficiency, GA-I, IVA and MSUD within the Dutch NBS program. Single-condition tools (SCTs) and multivariate approaches, including marker ratios and covariate adjustments, were evaluated for their ability to discriminate true- and false-positive referrals. For CPT1 deficiency, age-adjusted SCT combined with birthweight, location correction, and the C18:1/methionine ratio substantially reduced false positives. For GA-I, C3DC-based ratios improved specificity while preserving true-positive detection, potentially reflecting postnatal renal immaturity in some cases. For IVA, the dual scatter plot fully separated true- and false-positive referrals, highlighting the limitations of single-marker screening. For MSUD, differences between false-positive and true-positive cases were more pronounced, yet a similar number of false positives were still referred; valine-related markers contributed to false positives, while leucine and the Xle/Phe ratio better identified true positives. CLIR-based post-analytical tools enhanced NBS specificity through covariate-aware, multivariate interpretation. This provides important input for decision makers in both the Dutch NBS, as well as the NBS community worldwide.
Acrylate Patch Testing for Allergic Contact Dermatitis Over 28 Years: Hierarchical Clustering for Subgroup Analysis and Computational Optimization for Patch Test Selection
Colquitt, JennaKay , Yiannias, James A. , Davis, Mark D.P., Hall, Matthew R., Youssef, Molly J. , Yang, Yul W. , Colquitt, JennaKay , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17103568261479501 | PMID 42629958 Get It

Background: Acrylate allergy is rising, with many patients showing patch test positivity to multiple acrylates. Understanding acrylate sensitivity can guide avoidance and optimize screening. Objectives: To quantify acrylate patch test positivity, define subgroups using hierarchical clustering, and algorithmically optimize acrylate patch testing series. Methods: We conducted a retrospective review of 27 acrylate allergens patch tested at 3 Mayo Clinic sites (Arizona, Florida, Minnesota) from 1997 to 2024; 14 had ≥1% positivity. Pairwise copositivity rates were background-corrected and analyzed using hierarchical clustering, followed by computational optimization for patch test screening. Results: Among 17,148 patients, 90,818 tests yielded 1,557 positives (1.71%). Most frequent positive reactions were 2-hydroxyethyl acrylate 0.1% (HEA, 5.4%), 2-hydroxypropyl methacrylate 2% (HPMA, 5.0%), and 2-hydroxyethyl methacrylate 2% (HEMA, 4.6%). Clustering revealed 2 general subgroups, with ethyl cyanoacrylate 10% (ECA) showing minimal copositivity to other acrylates. Optimization analysis for screening showed that one allergen (HEMA) captured 49.4% of sensitized patients; 2 (HEMA + ECA) captured 72.2%. Four allergens, including HEMA, ECA, HEA, and diethylene glycol diacrylate 0.1% (DEGDA), captured >90%, and a 7-allergen series captured 100%, with no higher yield from additional acrylates in standard screening. Conclusions: Acrylate allergy is heterogeneous, comprising 2 subgroups, with cyanoacrylates co-reacting separately. Algorithm-guided series refinement improves diagnostic efficiency by prioritizing high-yield allergens for screening while minimizing unnecessary testing.
Refining MMA Screening in the Dutch Newborn Screening Program: Lessons from Vitamin B12 Deficiency and Genetic Cases
Meijer, Nils W. F., Koop, Klaas , Maase, Rose, Hall, Patricia L., Visser, Wouter F. , Oussoren, Esmeralda, Heiner‐Fokkema, M. Rebecca , Velden, Monique G.M. de Sain–van der , Bosch, Annet M , Heiner-Fokkema, M Rebecca , de Sain-van der Velden, Monique G M

Mayo Clinic

International Journal of Neonatal Screening | August 21, 2026 | Volume: 12 | Issue: 3 | Pages: 69

10.3390/ijns12030069 | PMID 42647256 Get It

Since October 2019, screening for methylmalonic acidemia (MMA) has been implemented in the Dutch Newborn Screening (NBS) program. Since implementation, most referrals for MMA have been the result of (maternal) vitamin B12 deficiency. Although vitamin B12 deficiency is an important condition and early detection can confer health benefits, its identification was not the original objective of the screening. We therefore examined whether genetic forms of MMA can be distinguished from acquired forms. Early distinction between these forms is essential for guiding clinical management, informing prognosis, and enabling appropriate genetic counseling. Specifically, we tested whether the use of Collaborative Laboratory Integrated Reports (CLIR) to complement NBS results improved specificity of the test for genetic MMAs. We found that with the use of CLIR, genetic conditions including methylmalonyl-CoA mutase (mut) deficiency and cobalamin (cbl) A, B, C and D deficiency can be partially differentiated from acquired causes. This results in a significant reduction in the number of second-tier tests required. However, this approach may also exclude certain other genetic causes. Based on all findings, we provide considerations and implications for MMA screening that may inform decision-makers in (other) NBS programs.
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms
Raeisi, Morteza, André, Thierry, Shi, Qian, Yoshino, Takayuki, Adams, Richard, Cremolini, Chiara, Meyerhardt, Jeffrey A, Tie, Jeanne, Cohen, Romain, Bachet, Jean‐Baptiste , Bando, Hideaki, Misumi, Toshihiro, Bokemeyer, Carsten, Koopman, Miriam, Heinemann, Volker, Peeters, Marc, Cutsem, Eric Van, Grothey, Axel, Gramont, Aimery de, André, Thierry , Shi, Qian , Yoshino, Takayuki , Raeisi, Morteza , Bando, Hideaki , André, Thierry , Shi, Qian , Yoshino, Takayuki , Bando, Hideaki , Adams, Richard , Cremolini, Chiara , Meyerhardt, Jeffrey A. , Tie, Jeanne , Cohen, Romain , Misumi, Toshihiro , Bokemeyer, Carsten, Saltz, Leonard B. , Koopman, Miriam , Heinemann, Volker , Cutsem, Eric Van , Grothey, Axel , Chibaudel, Benoist , Gramont, Aimery de

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag291 | PMID 42633557 Get It

Abstract Background Synthetic control arms (SCAs) derived from historical trial data can complement randomized controlled trials (RCTs), particularly in oncology where feasibility, ethical, and cost constraints may limit conventional trial designs. However, their validity for overall survival (OS) remains uncertain. We evaluated the feasibility and limitations of constructing SCAs from the ARCAD metastatic colorectal cancer (mCRC) database across multiple treatment lines. Methods Seven landmark RCTs representing first-, second-, and third-line settings were selected. External control arms were constructed from ARCAD individual patient-level data using propensity score matching based on key clinical and biological variables from a validated ARCAD prognostic score, with adjustment for geographic region and time era when needed. A prespecified two-step benchmarking framework assessed: (1) control-arm OS reproducibility and (2) virtual trial comparisons between matched synthetic controls and original RCT experimental arms. Agreement was evaluated using hazard ratios (HRs) and Z-tests. Results A total of 28,022 patients met the inclusion criteria. ARCAD-derived SCAs were successfully constructed for all selected RCTs and closely reproduced control-arm OS. After matching, baseline characteristics were well balanced, with minimal differences between included and excluded patients. Virtual trials showed concordant treatment-effect estimates with the original RCTs, with a median absolute HR deviation of 0.05 and no significant differences by Z-tests (P>.05). Survival outcomes were consistently reproduced across treatment lines. Conclusion ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC. Despite limitations related to residual confounding and missing data, this framework supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
Spatial multi-omics and single-cell transcriptomics uncover senescence-associated cellular programs during colon adenoma to cancer progression
Yu, Ming , Xie, Yumo , Allen, Lena, Carter, Kelly , Donato, Elizabeth , Cheng, Lingxin , Kendziorski, Christina , Hall, Lance T. , Marzo, Angelo M. De , Hicks, Jessica, Reddi, Deepti , Sun, Wei, Matkowskyj, Kristina A , De Marzo, Angelo M , Newell, Evan W , Grady, William M , Carter, Kelly , Reddi, Deepti , Sun, Wei, Grady, William M.

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.06.743310 | PMID 42620287 Get It

Abstract Colorectal cancer develops through a normal-adenoma-carcinoma sequence, yet only 5-10% of adenomas progress to malignancy, and the cellular programs governing that sequence remain poorly defined. Here we generate a spatial multi-omics atlas of human colon adenomas, combining Visium CytAssist and protein co-detection across 24 nonadvanced and advanced tubular adenomas with single-cell resolution Xenium Prime 5K profiling of 101 patient-matched normal, adenoma, and carcinoma cores from 16 patients. Integrating whole-transcriptome and 31-plex protein data identifies nine spatial clusters and two dysplastic epithelial populations that co-express stemness, proliferation, and senescence programs. These programs occupy a shared, spatially confined epithelial niche that expands from adenoma to carcinoma. Spatial analysis revealed GDF15, a senescence-associated secretory factor, mediated the coupling between senescence and stemness in advanced adenomas, and that GDF15-high epithelium locally excludes CD8+ T cells in adenoma and, more broadly, in carcinoma. These findings position senescence as a spatially instructive rather than merely tumor-suppressive program during colorectal carcinogenesis and suggest GDF15 might be a potential candidate target for cancer prevention and interception in the colon.
Glomerular-Targeted Delivery of Low-Dose Prednisolone Attenuates Established Lupus Nephritis in MRL/lpr Mice
Williams, Kristof , Agyekum, Georgina , Patne, Akshata, Markoutsa, Eleni, Chellappan, David Raj, Hall, Nathan, Tian, Zhi , Soto, Nohely Hernandez, Cuadrao, Sebastian, Lozonschi, Isabella, Fu, Liying, Haight, Lilliana, Sharma, Rahul, Mohapatra, Subhra, Wang, Lei, Liu, Ruisheng, Fu, Liying, Sharma, Rahul, Wang, Lei , Mohapatra, Shyam S. , Liu, Ruisheng

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.01.742194 Get It

Abstract Background Lupus nephritis remains a major cause of chronic kidney disease and kidney failure in systemic lupus erythematosus. Glucocorticoids are central to treatment but are limited by systemic toxicity. We evaluated whether a previously characterized collagen IV α3-targeted liposomal nanoparticle formulation carrying low-dose prednisolone could attenuate established lupus nephritis in MRL/lpr mice. Methods Female MRL/lpr mice with disease present at treatment initiation and C57BL/6J control mice received saline or collagen IV α3-targeted prednisolone-loaded nanoparticles (Col4-α3-Pred-NPs). Renal outcomes were assessed by longitudinal proteinuria, glomerular filtration rate (GFR), survival, kidney histopathology, renal IgG and C3d deposition, dUTP/TUNEL-associated injury staining, and renal cytokine/chemokine profiling. Body weight, food and water intake, and blood glucose were monitored as measures of general condition and preliminary tolerability. Results Col4-α3-Pred-NPs improved survival in MRL/lpr mice, reduced cumulative proteinuria burden, and attenuated terminal GFR decline compared with saline-treated MRL/lpr controls. Treatment reduced glomerular and tubulointerstitial injury, lowered composite EGTI histopathology scores, decreased terminal kidney enlargement, reduced glomerular IgG deposition and renal dUTP-positive injury signals, and reduced renal signals for IL-28A/B, IL-7, PD-ECGF, IL-11, CCL6/C10, and IL-15. C3d deposition was not significantly altered. Nanoparticle treatment was not associated with sustained treatment-related increases in blood glucose or body-weight loss during the measured study period. Conclusions Collagen IV α3-targeted liposomal delivery of low-dose prednisolone attenuated established lupus nephritis in MRL/lpr mice and improved renal structural, functional, inflammatory, and survival outcomes. These findings support further evaluation of glomerulus-targeted nanotherapy as a potential strategy to improve the precision and therapeutic index of glucocorticoid treatment in lupus nephritis.
The Challenge of Newborn Screening for All Urea Cycle Disorders
Hall, Patricia L., Matern, Dietrich

Mayo Clinic

Pediatrics | July 22, 2026 | Volume: 158 | Issue: 2 | Pages: No page available

10.1542/peds.2026-076409 | PMID 42481022 Get It